Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has ...

Brain natriuretic peptide (BNP), first discovered in porcine brain, is principally produced by the heart. Unlike atrial natriuretic peptide (ANP), BNP is largely derived from the ventricles.

The inactive N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) has been linked to ventricular dysfunction in the general population, and is predictive of cardiac events. Corteville ...

Luís Beck-da-Silva, MD; Adolfo de Bold, PhD, FRSC; Ross A. Davies, MD, FRCPC; Benjamin J.W. Chow, MD, FRCPC; Terrence D. Ruddy, MD, FRCPC; Margaret Fraser, RN ...

Secondary end points included changes in N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels, high-sensitivity cardiac troponin T levels, the 6-minute walk distance, and the New York ...

Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ...

Its partner hormones are atrial natriuretic peptides, secreted by heart cells. When the atrial natriuretic hormone binds to GC-A, the receptor is activated and sends a signal to the interior of ...

In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, ...

Emerging research highlights the cardiovascular benefits of popular anti-obesity medications, such as GLP-1-based therapies.

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...